vs
STANDARD BIOTOOLS INC.（LAB）与NATIONAL RESEARCH CORP（NRC）财务数据对比。点击上方公司名可切换其他公司
NATIONAL RESEARCH CORP的季度营收约是STANDARD BIOTOOLS INC.的1.8倍（$35.2M vs $19.6M），NATIONAL RESEARCH CORP净利率更高（5.1% vs -177.4%，领先182.5%），NATIONAL RESEARCH CORP同比增速更快（-4.6% vs -11.5%），NATIONAL RESEARCH CORP自由现金流更多（$6.1M vs $-23.1M），过去两年NATIONAL RESEARCH CORP的营收复合增速更高（-0.2% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
NRC Health（原国家研究公司）是一家美国医疗健康企业，1981年成立，总部位于内布拉斯加州林肯市。公司主要在美加两国提供医疗健康相关产品及订阅式解决方案，深耕区域医疗健康服务领域。
LAB vs NRC — 直观对比
营收规模更大
NRC
是对方的1.8倍
$19.6M
营收增速更快
NRC
高出6.8%
-11.5%
净利率更高
NRC
高出182.5%
-177.4%
自由现金流更多
NRC
多$29.1M
$-23.1M
两年增速更快
NRC
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $35.2M |
| 净利润 | $-34.7M | $1.8M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | 13.3% |
| 净利率 | -177.4% | 5.1% |
| 营收同比 | -11.5% | -4.6% |
| 净利润同比 | -28.8% | -72.6% |
| 每股收益（稀释后） | $-0.09 | $49.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABNRC
| Q4 25 | — | $35.2M | ||
| Q3 25 | $19.6M | $34.6M | ||
| Q2 25 | $21.8M | $34.0M | ||
| Q1 25 | $40.8M | $33.6M | ||
| Q4 24 | — | $36.9M | ||
| Q3 24 | $22.1M | $35.8M | ||
| Q2 24 | $22.5M | $35.0M | ||
| Q1 24 | $45.5M | $35.3M |
净利润LABNRC
| Q4 25 | — | $1.8M | ||
| Q3 25 | $-34.7M | $4.1M | ||
| Q2 25 | $-33.5M | $-106.0K | ||
| Q1 25 | $-26.0M | $5.8M | ||
| Q4 24 | — | $6.6M | ||
| Q3 24 | $-26.9M | $5.7M | ||
| Q2 24 | $-45.7M | $6.2M | ||
| Q1 24 | $-32.2M | $6.4M |
毛利率LABNRC
| Q4 25 | — | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — |
营业利润率LABNRC
| Q4 25 | — | 13.3% | ||
| Q3 25 | -168.5% | 22.4% | ||
| Q2 25 | -118.1% | 4.7% | ||
| Q1 25 | -80.8% | 25.6% | ||
| Q4 24 | — | 26.0% | ||
| Q3 24 | -120.9% | 22.3% | ||
| Q2 24 | -134.5% | 25.3% | ||
| Q1 24 | -132.2% | 24.8% |
净利率LABNRC
| Q4 25 | — | 5.1% | ||
| Q3 25 | -177.4% | 11.9% | ||
| Q2 25 | -153.7% | -0.3% | ||
| Q1 25 | -63.8% | 17.2% | ||
| Q4 24 | — | 17.8% | ||
| Q3 24 | -122.0% | 15.9% | ||
| Q2 24 | -203.3% | 17.6% | ||
| Q1 24 | -70.6% | 18.0% |
每股收益（稀释后）LABNRC
| Q4 25 | — | $49.58 | ||
| Q3 25 | $-0.09 | $0.18 | ||
| Q2 25 | $-0.09 | $-0.01 | ||
| Q1 25 | $-0.07 | $0.25 | ||
| Q4 24 | — | $0.27 | ||
| Q3 24 | $-0.07 | $0.24 | ||
| Q2 24 | $-0.12 | $0.26 | ||
| Q1 24 | $-0.27 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $4.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $14.0M |
| 总资产 | $539.6M | $134.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABNRC
| Q4 25 | — | $4.1M | ||
| Q3 25 | $129.4M | $2.2M | ||
| Q2 25 | $158.6M | $5.3M | ||
| Q1 25 | $150.9M | $2.5M | ||
| Q4 24 | — | $4.2M | ||
| Q3 24 | $210.6M | $3.5M | ||
| Q2 24 | $269.8M | $485.0K | ||
| Q1 24 | $287.1M | $1.7M |
总债务LABNRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | $48.7M | ||
| Q2 24 | $55.1M | $33.3M | ||
| Q1 24 | $55.0M | $35.2M |
股东权益LABNRC
| Q4 25 | — | $14.0M | ||
| Q3 25 | $399.7M | $14.3M | ||
| Q2 25 | $424.5M | $21.3M | ||
| Q1 25 | $454.6M | $29.7M | ||
| Q4 24 | — | $31.3M | ||
| Q3 24 | $489.3M | $34.6M | ||
| Q2 24 | $510.3M | $40.2M | ||
| Q1 24 | $577.3M | $36.9M |
总资产LABNRC
| Q4 25 | — | $134.9M | ||
| Q3 25 | $539.6M | $135.7M | ||
| Q2 25 | $557.0M | $141.4M | ||
| Q1 25 | $579.6M | $135.2M | ||
| Q4 24 | — | $132.5M | ||
| Q3 24 | $681.5M | $131.8M | ||
| Q2 24 | $708.7M | $119.1M | ||
| Q1 24 | $777.7M | $120.9M |
负债/权益比LABNRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | 1.41× | ||
| Q2 24 | 0.11× | 0.83× | ||
| Q1 24 | 0.10× | 0.95× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $7.2M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $6.1M |
| 自由现金流率自由现金流/营收 | -118.1% | 17.2% |
| 资本支出强度资本支出/营收 | 4.5% | 3.2% |
| 现金转化率经营现金流/净利润 | — | 3.99× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $15.7M |
8季度趋势，按日历期对齐
经营现金流LABNRC
| Q4 25 | — | $7.2M | ||
| Q3 25 | $-22.2M | $13.8M | ||
| Q2 25 | $-20.7M | $-1.1M | ||
| Q1 25 | $-30.3M | $6.6M | ||
| Q4 24 | — | $6.4M | ||
| Q3 24 | $-27.9M | $9.4M | ||
| Q2 24 | $-39.0M | $6.8M | ||
| Q1 24 | $-62.5M | $12.0M |
自由现金流LABNRC
| Q4 25 | — | $6.1M | ||
| Q3 25 | $-23.1M | $10.2M | ||
| Q2 25 | $-22.6M | $-4.1M | ||
| Q1 25 | $-35.3M | $3.7M | ||
| Q4 24 | — | $1.9M | ||
| Q3 24 | $-30.1M | $7.8M | ||
| Q2 24 | $-41.0M | $1.5M | ||
| Q1 24 | $-63.3M | $7.9M |
自由现金流率LABNRC
| Q4 25 | — | 17.2% | ||
| Q3 25 | -118.1% | 29.4% | ||
| Q2 25 | -103.6% | -12.2% | ||
| Q1 25 | -86.6% | 10.9% | ||
| Q4 24 | — | 5.2% | ||
| Q3 24 | -136.4% | 21.8% | ||
| Q2 24 | -182.2% | 4.3% | ||
| Q1 24 | -138.9% | 22.4% |
资本支出强度LABNRC
| Q4 25 | — | 3.2% | ||
| Q3 25 | 4.5% | 10.4% | ||
| Q2 25 | 8.7% | 8.8% | ||
| Q1 25 | 12.4% | 8.9% | ||
| Q4 24 | — | 12.0% | ||
| Q3 24 | 10.2% | 4.5% | ||
| Q2 24 | 8.6% | 15.0% | ||
| Q1 24 | 1.7% | 11.7% |
现金转化率LABNRC
| Q4 25 | — | 3.99× | ||
| Q3 25 | — | 3.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.15× | ||
| Q4 24 | — | 0.97× | ||
| Q3 24 | — | 1.66× | ||
| Q2 24 | — | 1.10× | ||
| Q1 24 | — | 1.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
NRC
暂无分部数据
